Airsonett AB
- Industry
- Medical Devices
- Founded Year
- 2010
- Headquarters
- ngelholm, Sweden
- Employee Count
- 15
Key People
-
Anders Due-Boje - CEO
Email: anders.due-boje@airsonett.eu
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: Experienced leadership with over a decade in MedTech.
CEO Anders Due-Boje has extensive experience in the MedTech industry, including roles as European Sales Director at Motorola and CEO of Neoventa. This positions the company well for strategic growth and market penetration.
- Clinical Need
-
Aspect: Strong
Summary: Addresses significant unmet needs in allergic asthma and eczema treatment.
Airsonett's Air4 device offers a non-pharmaceutical solution for patients with severe allergic asthma and eczema, conditions affecting millions globally. The device's ability to provide 99.5% allergen-free air during sleep meets a critical need for patients seeking alternative treatments.
- Competition
-
Aspect: Somewhat crowded
Summary: Competes in a market with several alternative treatments.
The market for allergic asthma and eczema treatments includes various pharmaceutical and non-pharmaceutical options. While Airsonett's Air4 offers a unique approach, it competes with established treatments, requiring effective differentiation and marketing strategies.
- Technical Challenge
-
Aspect: Predictable
Summary: Technology is well-developed with minimal technical risks.
The Air4 device utilizes patented Temperature-controlled Laminar Airflow (TLA) technology, which has been clinically validated and is already in use. This reduces technical uncertainties and supports reliable manufacturing and deployment.
- Patent
-
Aspect: Strong
Summary: Robust patent portfolio protecting core technology.
Airsonett holds patents for its TLA technology, providing a competitive edge and barriers to entry for potential competitors. This intellectual property protection supports the company's market position and valuation.
- Financing
-
Aspect: Medium
Summary: Secured significant funding but may require additional capital for expansion.
Airsonett has raised approximately SEK 300 million since its inception, with recent investments from SEB Venture Capital, Industrifonden, and others. While this funding supports current operations, further capital may be needed to scale production and expand market reach.
- Regulatory
-
Aspect: 510k/PMA
Summary: Achieved necessary regulatory approvals for market entry.
The Air4 device is CE marked as a Class 1 medical device and holds a 510(k) clearance from the FDA, allowing for distribution in key markets. These approvals facilitate market access and build credibility with healthcare providers and patients.
Opportunity Rollup
- Odds of Success
- 3.75
- Peak Market Share
- 5.05
- Segment CAGR
- 3.4%
- Market Segment
- Respiratory Devices
- Market Sub Segment
- Homecare Respiratory Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.25 |
| 2 | 0.76 |
| 3 | 1.77 |
| 4 | 3.54 |
| 5 | 5.05 |
Key Takeaway
Airsonett's Air4 device addresses a significant clinical need with its innovative non-pharmaceutical approach, supported by strong leadership and robust patents. However, market competition and financing needs pose challenges to achieving widespread adoption and financial success.